January 30, 2018 09:55 AM EST
R&D
Pharma

Eye­ing a multi­bil­lion-dol­lar mar­ket, Shire snags pre­clin­i­cal IVIg ri­val from AB Bio­sciences

Brittany Meiling

Shire $SH­PG is get­ting in ear­ly on an in­ves­ti­ga­tion­al prod­uct that might one day re­place IV in­fu­sions of con­cen­trat­ed an­ti­bod­ies giv­en to pa­tients to boost …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times